Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (trading symbol: OCX) on January 30, 2023. The filing addresses a material definitive agreement regarding the sale of a subsidiary. Note: The request metadata references "Insight Molecular Diagnostics Inc.," but the filing text explicitly identifies the registrant as Oncocyte Corporation.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. It is a disclosure of a corporate transaction event.
Material Changes and Transaction Details
- Transaction: Extension of the "Outside Date" for the sale of a majority stake in Razor Genomics Inc. (a wholly-owned subsidiary of Oncocyte).
- Original Agreement: Dated December 15, 2022, with Dragon Scientific, LLC as the buyer.
- Terms: Oncocyte agreed to sell 3,188,181 shares of Razor common stock (approximately 70% of fully-diluted equity). Post-closing, Oncocyte retains approximately 30% ownership.
- Amendment: The parties entered into a First Amendment on January 30, 2023, extending the deadline for the transaction closing from February 1, 2023, to February 15, 2023.
- Conditions: The agreement may be terminated if the closing does not occur by the new Outside Date. No other provisions were amended.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future performance, or specific risk factors beyond the inherent risk that the transaction may be terminated if the closing does not occur by the extended deadline of February 15, 2023.
Investor Verification Checklist
- Verify the final status of the Razor Genomics sale by the new deadline of February 15, 2023.
- Confirm whether the transaction closes or is terminated in subsequent filings.
- Review the full text of the First Amendment (Exhibit 10.1) for any undisclosed conditions.
- Monitor for any impact on Oncocyte's consolidated financial statements once the transaction concludes.